Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.5 EUR -1.63% Market Closed
Market Cap: 165.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanobiotix SA
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Total Receivables
€9.5m
CAGR 3-Years
15%
CAGR 5-Years
6%
CAGR 10-Years
15%
Valneva SE
PAR:VLA
Total Receivables
€30.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Total Receivables
€71m
CAGR 3-Years
72%
CAGR 5-Years
30%
CAGR 10-Years
44%
Inventiva SA
PAR:IVA
Total Receivables
€11m
CAGR 3-Years
25%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Total Receivables
€31.6m
CAGR 3-Years
-17%
CAGR 5-Years
12%
CAGR 10-Years
14%
OSE Immunotherapeutics SA
PAR:OSE
Total Receivables
€7.6m
CAGR 3-Years
-13%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
164.9m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
5.23 EUR
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Total Receivables?
Total Receivables
9.5m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Total Receivables amounts to 9.5m EUR.

What is Nanobiotix SA's Total Receivables growth rate?
Total Receivables CAGR 10Y
15%

Over the last year, the Total Receivables growth was 771%. The average annual Total Receivables growth rates for Nanobiotix SA have been 15% over the past three years , 6% over the past five years , and 15% over the past ten years .

Back to Top